Patents Assigned to ALS Therapy Development Institute
-
Patent number: 11857534Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).Type: GrantFiled: January 26, 2022Date of Patent: January 2, 2024Assignee: ALS Therapy Development InstituteInventors: Fernando G. Vieira, Alan Premasiri, Anna Gill
-
Patent number: 11708349Abstract: Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: GrantFiled: February 15, 2019Date of Patent: July 25, 2023Assignee: ALS Therapy Development InstituteInventors: Alan Gill, Steven Perrin
-
Patent number: 11692040Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: May 17, 2021Date of Patent: July 4, 2023Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 11660324Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 24, 2020Date of Patent: May 30, 2023Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
-
Patent number: 11607402Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).Type: GrantFiled: June 8, 2020Date of Patent: March 21, 2023Assignee: ALS Therapy Development InstituteInventors: Fernando G. Vieira, Alan Premasiri, Anna Gill
-
Patent number: 11384152Abstract: Anti-CD40L antibodies and antigen binding fragments thereof, compositions comprising the antibodies or antigen binding fragments, Anti-CD40L antibodies with reduced effector function, and method of using same for treatment of CD40L-related diseases or disorders.Type: GrantFiled: May 23, 2018Date of Patent: July 12, 2022Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventor: Alexey Lugovskoy
-
Publication number: 20210269538Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: ApplicationFiled: May 17, 2021Publication date: September 2, 2021Applicant: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 11014990Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: May 13, 2020Date of Patent: May 25, 2021Assignee: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Publication number: 20200277391Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: ApplicationFiled: May 13, 2020Publication date: September 3, 2020Applicant: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 10683356Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: September 7, 2018Date of Patent: June 16, 2020Assignee: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 10106618Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: GrantFiled: August 2, 2017Date of Patent: October 23, 2018Assignee: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Publication number: 20170342158Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: ApplicationFiled: August 2, 2017Publication date: November 30, 2017Applicant: ALS Therapy Development InstituteInventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Patent number: 9044459Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia.Type: GrantFiled: April 8, 2013Date of Patent: June 2, 2015Assignee: ALS THERAPY DEVELOPMENT INSTITUTEInventors: Steven Perrin, John Monteith Lincecum, Alan Gill, Fernando Vieira
-
Patent number: 8946301Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.Type: GrantFiled: November 29, 2012Date of Patent: February 3, 2015Assignee: ALS Therapy Development InstituteInventors: Steven Perrin, John Lincecum, Alan Gill, Fernando Vieira
-
Patent number: 8673308Abstract: Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.Type: GrantFiled: February 23, 2012Date of Patent: March 18, 2014Assignee: ALS Therapy Development InstituteInventors: Steven Perrin, John Lincecum, Alan Gill, Fernando Vieira
-
Publication number: 20130150454Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.Type: ApplicationFiled: November 29, 2012Publication date: June 13, 2013Applicant: ALS THERAPY DEVELOPMENT INSTITUTEInventor: ALS THERAPY DEVELOPMENT INSTITUTE
-
Patent number: 8435514Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.Type: GrantFiled: December 4, 2009Date of Patent: May 7, 2013Assignee: ALS Therapy Development InstituteInventors: Steven Perrin, John Monteith Lincecum, Alan Gill, Fernando Vieira
-
Publication number: 20120237505Abstract: Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.Type: ApplicationFiled: February 23, 2012Publication date: September 20, 2012Applicant: ALS Therapy Development InstituteInventors: Steven Perrin, John Lincecum, Alan Gill, Fernando Vieira
-
Publication number: 20110293612Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.Type: ApplicationFiled: December 4, 2009Publication date: December 1, 2011Applicant: ALS Therapy Development InstituteInventors: Steven Perrin, John Monteith Lincecum, Alan Gill, Fernando Vieira
